IRWD — Ironwood Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $589.91m
- $895.78m
- $296.15m
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ironwood Q2 revenue rises 33%
Brief: Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026
Brief: FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation
Brief: Ironwood Pharmaceuticals Inc - Gregory Martini Resigns As CFO Effective May 15, 2026 - SEC Filing
Ironwood Q1 revenue jumps 159%, beats analyst expectations
Brief: Ironwood Pharmaceuticals Satisfies Liquidity Conditions In Credit Agreement On March 10
Ironwood Pharma Q4 revenue misses analyst expectations due to pricing challenges
U.S. STOCKS ON THE MOVE-Ulta Beauty and Berkshire Hathaway
U.S. STOCKS ON THE MOVE-Rivian, Tesla, MGM Resorts
U.S. STOCKS ON THE MOVE-Micron, Ironwood Pharmaceuticals, Chipotle Mexican Grill
Ironwood Pharma jumps after 2026 revenue forecast above estimates
U.S. STOCKS ON THE MOVE-Nucor, Natgas companies, health insurers
U.S. STOCKS ON THE MOVE-Robinhood Markets, Oracle, Grindr
U.S. STOCKS ON THE MOVE-CleanSpark, Salesforce, Tesla
Ironwood rises after US sets Medicare price for constipation drug
Brief: Ironwood Pharmaceuticals Inc - HHS Releases Maximum Fair Price For Linzess - SEC Filing
Ironwood Pharmaceuticals beats Q3 revenue estimates, raises outlook
Brief: FDA Approves Linzess Capsules For Children Aged 7 And Older With IBS With Constipation